复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

提前休市 12-24 12:08:29

23.900

+0.000

0.00%

最高24.000	最低23.850	成交量52.02万
今开23.950	昨收23.900	日振幅0.63%
总市值129.90亿	流通市值38.96亿	总股本5.43亿
成交额1,245万	换手率0.32%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":23.9,"timestamp":1735013309016,"preClose":23.9,"halted":0,"volume":520200,"delay":0,"floatShares":163000000,"shares":543494853,"eps":1.0681041,"marketStatus":"提前休市","marketStatusCode":6,"change":0,"latestTime":"12-24 12:08:29","open":23.95,"high":24,"low":23.85,"amount":12448110,"amplitude":0.006276,"askPrice":23.9,"askSize":10700,"bidPrice":23.85,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":1.3496986084174063,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735263000000},"adr":0,"listingDate":1569340800000,"adjPreClose":23.9,"openAndCloseTimeList":[[1735003800000,1735012800000]],"volumeRatio":0.984428,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696/wiki","defaultTab":"wiki","newsList":[{"id":"2493461387","title":"复星医药(02196.HK)：吸收合并复宏汉霖(02696.HK)前提条件已达成","url":"https://stock-news.laohu8.com/highlight/detail?id=2493461387","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493461387?lang=zh_cn&edition=full","pubTime":"2024-12-24 08:59","pubTimestamp":1735001940,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，截至上周一(16日)，就对控股子公司复宏汉霖(02696.HK) 实施吸收合并及私有化交易协议生效的前提条件均已达成，当中包括取得国家发改委及其他主管部门审批、备案或登记等。复宏汉霖将于2025年1月22日召开临时股东大会及H股类别股东大会就与本次交易相关的议案进行审议。(gc/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-23 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1406096/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0028","BK0175","BK0188","BK1191","BK0187","BK1593","02196","02696","BK0096","BK0012","BK0060","BK0183","600196","BK0239","BK1161","BK0196","BK1515"],"gpt_icon":0},{"id":"2493579275","title":"音频 | 格隆汇12.23盘前要点—港A美股你需要关注的大事都在这","url":"https://stock-news.laohu8.com/highlight/detail?id=2493579275","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493579275?lang=zh_cn&edition=full","pubTime":"2024-12-23 07:41","pubTimestamp":1734910892,"startTime":"0","endTime":"0","summary":"上周五美股指数涨超1%，英伟达涨超3%；瑞银指美股前景仍乐观；TikTok可在美继续运营？特朗普发话；大众声明，将裁员3.5万人；暴涨99%！小游戏市场规模增长令人震惊；社零数据大降，北京、上海都不消费了？多地养殖场爆发鸭疫...","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/109.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/109.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1515593","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2493027382","title":"复宏汉霖获股东林利军增持102.06万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2493027382","media":"格隆汇资讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493027382?lang=zh_cn&edition=full","pubTime":"2024-12-23 06:45","pubTimestamp":1734907535,"startTime":"0","endTime":"0","summary":"格隆汇12月23日丨根据联交所最新权益披露资料显示，2024年12月17日-12月19日，复宏汉霖(02696.HK)获股东林利军在场内以每股均价23.4876-23.83港元合计增持102.06万股，涉资约2415.9万港元。增持后，林利军最新持股数目为9,924,084股，持股比例由4.99%上升至6.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223064539a202fd75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223064539a202fd75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2493443042","title":"复宏汉霖将完成私有化：拟明年2月初退市 成复星旗下又一摘牌企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2493443042","media":"雷递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493443042?lang=zh_cn&edition=full","pubTime":"2024-12-22 22:03","pubTimestamp":1734876201,"startTime":"0","endTime":"0","summary":"雷递网 雷建平 12月22日在宝宝树被强制退市，复星旅文宣布要私有化之际，复星旗下上市企业复宏汉霖的私有化也取得积极进展。截至今日，复宏汉霖股价为23.9港元，市值为129.9亿港元。截至目前，复宏汉霖处于停牌阶段，公司股价为18.84港元，市值为102亿港元。复星旅文称，此次私有化提案是基于复星旅文长期发展战略所做出的关键决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222221641a202489a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222221641a202489a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161","02196","BK1191","BK1593","BK1515"],"gpt_icon":0},{"id":"2493438912","title":"复宏汉霖拟被复星新药吸收合并","url":"https://stock-news.laohu8.com/highlight/detail?id=2493438912","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493438912?lang=zh_cn&edition=full","pubTime":"2024-12-22 19:13","pubTimestamp":1734866027,"startTime":"0","endTime":"0","summary":"复宏汉霖（02696）发布公告，宣布由复星新药对公司进行吸收合并的提案。合并后，公司将撤销H股上市，预计在2025年1月22日召开临时股东大会，审议合并及相关事项。合并对股东的影响包括提供每股H股24.6港元的现金选择，和每股非上市股份22.44元的现金选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412223275184336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2493107842","title":"复星医药寄发有关以吸收合并复宏汉霖并私有化的文件","url":"https://stock-news.laohu8.com/highlight/detail?id=2493107842","media":"观点网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493107842?lang=zh_cn&edition=full","pubTime":"2024-12-22 18:34","pubTimestamp":1734863640,"startTime":"0","endTime":"0","summary":"观点网讯：12月22日，上海复星医药（集团）股份有限公司、上海复宏汉霖生物技术股份有限公司发布联合公告，宣布寄发有关以吸收合并复宏汉霖方式，由复星新药对复宏汉霖私有化建议的综合文件。根据公告，综合文件已于同日寄发，详细阐述了私有化的具体条款和条件。此次私有化临时股东大会及H股类别股东大会的日期定于2025年1月22日，股份过户登记手续将从2025年1月17日暂停至同月22日。经独立董事委员会批准，董事会已委任浤博资本有限公司为独立财务顾问，以就合并向独立董事委员会提供意见 。预计所有生效条件将在2025年1月22日达成，届时H股在联交所的最后交易日为2025年2月4日下午4时10分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222184108ab8b37e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222184108ab8b37e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600196","BK1593","BK1515","BK1191","02696","02196","BK1161"],"gpt_icon":0},{"id":"2492410871","title":"林利军增持复宏汉霖(02696)21.88万股 每股作价23.83港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492410871","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492410871?lang=zh_cn&edition=full","pubTime":"2024-12-20 20:31","pubTimestamp":1734697879,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，12月19日，林利军增持复宏汉霖(02696)21.88万股，每股作价23.83港元，总金额约为521.40万港元。增持后最新持股数目约为992.41万股，最新持股比例为6.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2492959424","title":"复宏汉霖12月20日主力资金流出476万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2492959424","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492959424?lang=zh_cn&edition=full","pubTime":"2024-12-20 16:15","pubTimestamp":1734682515,"startTime":"0","endTime":"0","summary":"12月20日, 复宏汉霖股价涨0.21%，报收23.90元，成交金额1458万元，换手率0.37%，振幅0.63%，量比0.66。复宏汉霖今日主力资金净流出476万元，连续3日净流出，上一交易日主力净流出503万元，今日环比减少5.37%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为25.00%，平均跌幅为0.65%。该股近5个交易日上涨7.66%，主力资金累计净流出1094万元；近20日主力资金累计净流出669万元，其中净流出天数为6日。该股主力净额占比0.12%，港股市场排名2624/2653。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220161532a1fd2758&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220161532a1fd2758&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2492430160","title":"复宏汉霖与Palleon就一款在研抗肿瘤用药达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2492430160","media":"新京报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492430160?lang=zh_cn&edition=full","pubTime":"2024-12-20 09:28","pubTimestamp":1734658088,"startTime":"0","endTime":"0","summary":"截至目前，在肿瘤以及自身免疫类疾病治疗领域，全球范围内尚无已上市的唾液酸酶融合蛋白产品。复宏汉霖就本次合作将向Palleon支付合计至多5280万美元的开发里程碑款；基于许可产品在许可区域的净销售额达成情况，支付合计至多4250万美元的销售里程碑款；以及按照许可产品在许可区域的年度净销售额达成情况、按约定比例区间向Palleon支付特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220093241ab85afbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220093241ab85afbf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2492543211","title":"金十数据整理：每日港股市场要闻速递（12月20日 周五）","url":"https://stock-news.laohu8.com/highlight/detail?id=2492543211","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492543211?lang=zh_cn&edition=full","pubTime":"2024-12-20 08:59","pubTimestamp":1734656375,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["603259","07226","159837","EURmain","LU0149721374.USD","ETH","01398","LU1688375341.USD","TNmain","LU0128522744.USD","601398","02598","LU1196710864.SGD","LU0029875118.USD","00999","FXE","LU2362541513.USD","02359","02005","HTCD.SI","EUO","IE00BZ1G4Q59.USD","LU2237443895.HKD","00700","ZBmain","02511","UBmain","600036","80700","LU2045819591.USD","MEURmain","002352","03143","LU0106252389.USD","03968","HSCEI","SG9999000327.SGD","SG9999001903.USD","ZFmain","ZNmain","02696","ZTmain","06936","YANG","LU0882574139.USD","LU0163747925.USD","LU1720050803.USD","TCEHY","HSTECH"],"gpt_icon":0},{"id":"2492581431","title":"集采开标，人工耳蜗降至5万元左右；复宏汉霖牵手Palleon | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2492581431","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492581431?lang=zh_cn&edition=full","pubTime":"2024-12-20 07:54","pubTimestamp":1734652451,"startTime":"0","endTime":"0","summary":"本次集采人工耳蜗类耗材单套价格从平均20余万元降至5万元左右。预计2025年3月落地人工耳蜗中选结果。根据协议，Palleon有资格获得高达9530万美元的开发和商业化里程碑付款，以及E-602实现中国商业化后的销售特许权使用费。据此操作，风险自担。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220075621a1fc378c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220075621a1fc378c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","09939","BK1574","BK1161","02696"],"gpt_icon":0},{"id":"2492395364","title":"音频 | 格隆汇12.20盘前要点—港A美股你需要关注的大事都在这","url":"https://stock-news.laohu8.com/highlight/detail?id=2492395364","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492395364?lang=zh_cn&edition=full","pubTime":"2024-12-20 07:43","pubTimestamp":1734651794,"startTime":"0","endTime":"0","summary":"道指终结10连跌，美光科技跌超16%；美元指数续创逾两年新高；首发经济迎政策利好，商务部发声；卖一辆亏一两万！余承东透露；“豆包概念”遭热炒，字节提示风险；多城市房贷利率上调...","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/109.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/109.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1506402","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2492743647","title":"智通港股早知道 | 商务部加快出台政策文件推进首发经济 11月份全社会用电量同比增长2.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492743647","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492743647?lang=zh_cn&edition=full","pubTime":"2024-12-20 07:34","pubTimestamp":1734651286,"startTime":"0","endTime":"0","summary":"培育壮大新型消费，加快出台推进首发经济的政策文件，发展冰雪经济、银发经济，促进数字消费、绿色消费、健康消费。国家能源局：11月份全社会用电量同比增长2.8%11月份，全社会用电量7849亿千瓦时，同比增长2.8%。香港联交所收到来自市场各界共261份回应意见。商务部回应美方考虑禁售TPLink路由器商务部12月19日下午举行例行新闻发布会。供应链及国际业务收入为63.94亿元，同比增长21.65%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["80388","LU0348827113.USD","LU0762540952.USD","LU0797268264.HKD","LU1481107354.HKD","LU0516423091.SGD","LU0650527681.SGD","LU1044876610.USD","LU0072913022.USD","00388","LU0211977185.USD","LU1044874839.SGD","LU1366334651.USD","YANG","LU0516422440.USD","LU0348735423.USD","LU0594300419.USD","LU0561508036.HKD","02696","LU0918141705.HKD","LU0327786744.USD","LU1993786604.SGD","LU0197773160.USD","LU0048597586.USD","IE00BZ08YR35.GBP","SG9999004220.SGD","LU0873338254.USD","BK1516","LU0197773673.USD","LU0630378429.USD","BK1610","LU0540923850.HKD","LU2226246903.HKD","BK1518","LU0577902298.EUR","LU0516423174.USD","LU0370786039.SGD","LU0348825331.USD","HKXCY","LU0577902538.SGD","LU2257852520.SGD","HSCEI","LU2039709279.SGD","LU0831093199.SGD","IE00BZ08YT58.USD","02013","HSTECH","SG9999001846.SGD","IE00B3T34201.USD"],"gpt_icon":1},{"id":"2492106308","title":"复宏汉霖(02696.HK)与Palleon订立合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492106308","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492106308?lang=zh_cn&edition=full","pubTime":"2024-12-20 00:30","pubTimestamp":1734625800,"startTime":"0","endTime":"0","summary":"复宏汉霖(02696.HK) 公布，与Palleon订立合作及许可协议，据此，双方同意就E-602及联合疗法用于人类疾病治疗的全球合作开发及于各自许可区域内的商业化作出约定。本次合作不涉及首付款，公司将向Palleon支付里程碑款项合计不超过9,530万美元，以及以年度净销售额8%-12%计的特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-19 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405369/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2492120570","title":"复星医药子公司复宏汉霖与Palleon签署许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492120570","media":"北京商报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492120570?lang=zh_cn&edition=full","pubTime":"2024-12-19 20:57","pubTimestamp":1734613061,"startTime":"0","endTime":"0","summary":"12月19日晚间，复星医药发布公告称，公司控股子公司复宏汉霖与Palleon签订《合作与许可协议》，根据约定，双方将基于各自专利及专有技术，就Palleon在研产品E-602及相关联合治疗方案于领域内的全球合作开发及于各自许可区域内的商业化开展合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219210704a1fb320f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219210704a1fb320f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1593","BK1191","02196","BK1161","02696"],"gpt_icon":0},{"id":"2492124769","title":"聚焦自免疾病，复宏汉霖与Palleon合作推进糖编辑疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2492124769","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492124769?lang=zh_cn&edition=full","pubTime":"2024-12-19 20:20","pubTimestamp":1734610855,"startTime":"0","endTime":"0","summary":"Palleon是一家领先的专注开发糖免疫药物用于治疗癌症和炎症性疾病的公司。复宏汉霖将负责E-602联合汉利康用于治疗LN在中国的临床开发并承担相应资金。此次合作进一步扩展了复宏汉霖与Palleon的合作。复宏汉霖执行董事、首席执行官朱俊博士我们很高兴能与糖免疫这一新兴领域的领导者——Palleon进一步扩大合作。汉利康是目前国内唯一获批用于自身免疫疾病治疗的利妥昔单抗产品。据悉，E-602是Palleon的EAGLE糖编辑平台开发的同类首创的人唾液酸酶融合蛋白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121920205995ea773f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121920205995ea773f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2492121122","title":"复宏汉霖与Palleon签署合作协议，开发新型免疫治疗产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2492121122","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492121122?lang=zh_cn&edition=full","pubTime":"2024-12-19 20:00","pubTimestamp":1734609600,"startTime":"0","endTime":"0","summary":"财中社12月19日电复宏汉霖 发布公告，宣布与Palleon Pharmaceuticals Inc.签署了一项合作及许可协议。根据该协议，双方将就E-602及联合疗法在全球范围内进行合作开发和商业化。公司将获得Palleon在中国的独家许可，而Palleon则在全球其他地区拥有该产品的许可权。此次合作不涉及首付款，但公司需向Palleon支付最高5280万美元的开发里程碑款项，以及最高4250万美元的销售里程碑款项。该合作有望推动公司在肿瘤及自身免疫疾病治疗领域的研发进展，提升市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219200458ab845b07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219200458ab845b07&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2492912523","title":"复宏汉霖就E-602及联合疗法与PALLEON订立合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492912523","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492912523?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:47","pubTimestamp":1734605227,"startTime":"0","endTime":"0","summary":"合作及许可协议订立后，公司拟开展有关许可产品联合汉利康用于治疗狼疮肾炎适应症的临床研究。本次合作有望借助许可产品增强汉利康对自身免疫疾病的治疗效果。公司已与Palleon就两款肿瘤相关靶点唾液酸酶融合蛋白建立良好合作关系。本次合作有望基于双方现有技术，共同推进许可产品及联合疗法的研发，进一步丰富公司产品管线，进而增强公司在肿瘤及自身免疫类疾病治疗领域的综合市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219185050ab84385b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219185050ab84385b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2492406481","title":"复宏汉霖(02696)：就E-602及联合疗法与PALLEON订立的合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492406481","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492406481?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:33","pubTimestamp":1734604422,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，公司已于2024年12月19日与Palleon Pharmaceuticals Inc.订立一份合作及许可协议，据此，双方同意就E-602及联合疗法用于人类疾病治疗的全球合作开发及于各自许可区域内的商业化作出约定。合作及许可协议订立后，公司拟开展有关许可产品联合汉利康用于治疗狼疮肾炎适应症的临床研究。本次合作有望借助许可产品增强汉利康对自身免疫疾病的治疗效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2492147708","title":"复星医药：控股子公司签署药品合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492147708","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492147708?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:27","pubTimestamp":1734604032,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","BK1191","BK1593","BK1583","02196","BK0239","03347","BK0188","600196","BK0012","BK1576","BK0196","BK0175","BK0187","BK0028","BK0060","BK0183","BK0096","BK1515","02696","BK1141"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0742},{"period":"1month","weight":0.1802},{"period":"3month","weight":0.0391},{"period":"6month","weight":0.0575},{"period":"1year","weight":1.0427},{"period":"ytd","weight":0.7194}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":0.034},{"period":"3month","weight":0.0464},{"period":"6month","weight":0.0991},{"period":"1year","weight":0.2168},{"period":"ytd","weight":0.1663}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。该公司的主要产品包括利妥昔单抗注射液HLX01（汉利康）、赫赛汀（曲妥珠单抗）生物类似药HLX02、修美乐（阿达木单抗）生物类似药HLX03和安维汀（贝伐珠单抗）生物类似药HLX04以及候选生物创新药，包括HLX06（一种新型VEGFR2抑制剂）、HLX07（一种EGFR抑制剂）、HLX10（一种新型PD-1抑制剂）、HLX20（一种新型PD-L1抑制剂）及HLX22（一种新型HER2抑制剂）等。该公司还提供相关技术服务。该公司主要在中国境内和美国开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.004462},{"month":2,"riseRate":0.6,"avgChangeRate":0.003175},{"month":3,"riseRate":0.4,"avgChangeRate":-0.070667},{"month":4,"riseRate":0.8,"avgChangeRate":0.127521},{"month":5,"riseRate":0.4,"avgChangeRate":-0.068918},{"month":6,"riseRate":0.6,"avgChangeRate":0.1049},{"month":7,"riseRate":0.4,"avgChangeRate":0.0182},{"month":8,"riseRate":0.4,"avgChangeRate":-0.051626},{"month":9,"riseRate":0,"avgChangeRate":-0.146246},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.017718},{"month":11,"riseRate":0.666667,"avgChangeRate":0.070363},{"month":12,"riseRate":0.833333,"avgChangeRate":0.002729}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}